SCHEMBL359064

SCHEMBL359064

CCC(C)[C@H](NC(C)=O)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.66
L3MBTL1 Q9Y468 1/20 0.56
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
FPR2 P25090 3/20 0.49
ATM Q13315 1/20 0.49
CA2 P00918 3/20 0.46
CA1 P00915 2/20 0.46
ENPEP Q07075 2/20 0.44
MAPK1 P28482 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
MME P08473 1/20 0.44
ACE P12821 1/20 0.44
CPA1 P15085 1/20 0.44
ACE2 Q9BYF1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL359065 1.00 ALDH1A1 (0.66) ALDH1A1L3MBTL1KMT2AMEN1SMN1; SMN2
SCHEMBL428458 1.00 ALDH1A1 (0.66) ALDH1A1L3MBTL1KMT2AMEN1SMN1; SMN2
SCHEMBL7775372 1.00 ALDH1A1 (0.66) ALDH1A1L3MBTL1KMT2AMEN1SMN1; SMN2
SCHEMBL6026558 1.00 ALDH1A1 (0.66) ALDH1A1L3MBTL1KMT2AMEN1SMN1; SMN2
SCHEMBL6026559 1.00 ALDH1A1 (0.66) ALDH1A1L3MBTL1KMT2AMEN1SMN1; SMN2
SCHEMBL9502850 1.00 ALDH1A1 (0.66) ALDH1A1L3MBTL1KMT2AMEN1SMN1; SMN2
SCHEMBL15692297 0.92 ALDH1A1 (0.58) ALDH1A1L3MBTL1KMT2AMEN1SMN1; SMN2
SCHEMBL9073718 0.87 ALDH1A1 (0.56) ALDH1A1L3MBTL1KMT2AMEN1SMN1; SMN2
SCHEMBL9073717 0.87 ALDH1A1 (0.56) ALDH1A1L3MBTL1KMT2AMEN1SMN1; SMN2
SCHEMBL10866724 0.86 ALDH1A1 (0.59) ALDH1A1L3MBTL1KMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114106050-B Compact chiral environment biphenanthrene skeleton chiral phosphoric acid and preparation method and application thereof 华东理工大学 2024-01-12 CN claimed
CN-112574033-B Synthesis method of 1-hydroxy-2,5,8-trimethyl-9-fluorenone 江西中医药大学 2023-08-04 CN claimed
CN-106905100-B Resolution method of chiral amine compound and intermediate thereof 联化科技(台州)有限公司 2022-07-15 CN claimed
CN-114106050-A Tight chiral environment biphenyl-phenanthrene framework chiral phosphoric acid and preparation method and application thereof 华东理工大学 2022-03-01 CN claimed
CN-108774206-B Preparation method of compound containing isochroman-1-ketone skeleton 山西大学 2021-11-19 CN claimed
CN-112876507-A Trisubstituted olefin tertiary phosphine compound and preparation method thereof 湖北大学 2021-06-01 CN claimed
CN-112574033-A Synthesis method of 1-hydroxy-2,5,8-trimethyl-9-fluorenone 江西中医药大学 2021-03-30 CN claimed
CN-108187824-B turntable type crushing and compressing device for underground sewage treatment engineering and working method thereof XUZHOU INSTITUTE OF TECHNOLOGY (CN) 2019-12-10 CN claimed
US-20140127144-A1 Flavour Modifying Compounds GIVAUDAN S. A. (CH) 2014-05-08 US claimed
EP-1689703-A1 RESOLUTION OF 3-AMINO ALKYLNITRILES Pfizer Products Inc. (US) 2006-08-16 EP claimed
US-7026345-B2 Resolution of 3-amino alkylnitriles PFIZER INC. (US) 2006-04-11 US claimed
US-20050107453-A1 Resolution of 3-amino alkylnitriles PFIZER INC. 2005-05-19 US claimed
WO-2005040097-A1 RESOLUTION OF 3-AMINO ALKYLNITRILES PFIZER PRODUCTS INC. (US) 2005-05-06 WO claimed
EP-0126886-B1 PROCESS FOR THE SEPARATION OF L-LEUCINE AND L-ISOLEUCINE Degussa Aktiengesellschaft (DE) 1986-06-11 EP claimed
US-4562153-A Process for the separation of L-leucine and L-isoleucine DEGUSSA AKTIENGESELLSCHAFT (DE) 1985-12-31 US claimed
EP-0126886-A2 Process for the separation of L-leucine and L-isoleucine Degussa Aktiengesellschaft (DE) 1984-12-05 EP claimed
JP-58085896-A None JP disclosed
CN-118530141-B Aromatic hydrazide compound, preparation method and sterilization application thereof 聊城大学 2025-02-07 CN disclosed
EP-0061172-A1 Phosphorus-containing oligopeptides, processes for preparation thereof and a pharmaceutical composition containing the same KYOWA HAKKO KOGYO CO., LTD. (JP) 1982-09-29 EP disclosed
JP-S05885896-A 0001-01-01 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140127144-A1 Flavour Modifying Compounds TAS2R1, TAS1R2, TAS2R5 ALDH1A1 2550/4885L3MBTL1 1650/4885KMT2A 1026/4885
US-20050107453-A1 Resolution of 3-amino alkylnitriles AADAT, AANAT, AAAS ALDH1A1 1229/4885L3MBTL1 2374/4885KMT2A 3208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.